Moderna said that it’s on track to finish enrollment for a phase 3 study of its vaccine by the end of September. The company reported a fivefold increase in its Q2 revenue to $66.4 million.
Moderna (MRNA) stock price is rising. The rally is fueled by the company’s announcement that its COVID-19 vaccine candidate produced neutralizing antibodies in all 45 participants.
Moderna (MRNA) stock is up over 18% in the pre-market after adding 4.54% yesterday. The spike is attributed to the announcement that the coronavirus vaccine trial demonstrated a robust immune response.
Following Moderna CEO’s big expectations on mRNA-1273 distribution, Moderna shares jumped. On June 18, Moderna stock rose by 2.59% to close at $64.95. In pre-market today, Moderna shares are 0.08% up.
The coronavirus pandemic is raging and there’s still no treatment or vaccine. Regardless, let’s look at the stocks of two major biotech companies: Gilead Sciences and Moderna.
Moderna (MRNA) is up today. The rise may be attributed to news that the company’s coronavirus vaccine has passed a safety test on animals. Moreover, Israel is in talks with the company to buy its vaccine.
Moderna (MRNA) stock price is climbing to its ATH of $69 again. Currently, the shares are trading at around $63.
Moderna (MRNA) stock is trading at around $58.48 now, while the shares closed yesterday at $59.10. As the COVID-19 pandemic is still a threat for us, Moderna’s mRNA-1273 makes the company popular among investors.
Though now Moderna (MRNA) stock is significantly below its ATH, Oppenheimer analyst predicts an 80% increase from the current level.
It has been revealed that Moderna has already enrolled the first participants in its phase 2 clinical trial testing of the mRNA-1273 vaccine. Meanwhile, today MRNA stock is down.
Moderna (MRNA) shares price us slightly up despite the investors’ concerns about stock sales. The stock has lost around $20 from its ATH of $80.
Moderna (MRNA) stock price fell yesterday. This happened as both Merck and Novavax are set to go into COVID-19 vaccine trials.
The Moderna episode is a case study of how the coronavirus pandemic and the desperate hunt for treatments and vaccines are shaking up the financial markets. Now Moderna (MRNA) stock is trading below $70 again.
Moderna (MRNA) stock price keeps rising today. Dr. Anthony Fauci is rather optimistic about the coronavirus vaccine candidate that is being developed by Moderna.
Moderna chairman Noubar Afeyan assured people of the company’s fidelity to statistical accuracy concerning its vaccine trials. MRNA stock price went up yesterday.